Content and data provided by various third parties and Fidelity − Terms of Use | Help/Glossary
Research > ETFs > ETF / ETP Commentary > 

3 Reasons HTEC Stands Out Among the Best Health Tech ETFs 

BY | ETF Database
7:04 am ET 11/05/26 | 15 VIEWS
Every day, headlines extoll the potential in AI investing, and the markets reflect that; the biggest companies in the S&P 500 include the key AI hyperscalers. Still, the impact of AI will be much deeper and more widespread than that — especially in other tech-heavy segments. Health care is poised to change massively. The best health tech ETFs out there can offer powerful exposure therein, with the ROBO Global Healthcare Tech ETF (HTEC B) standing out.Key Takeaways: The AI revolution touches on all aspects of the economy, including health care technology. HTEC offers a strong approach to that space, tracking the ROBO Global Healthcare Technology and Innovation Index. The fund has returned 24.7% YTD, according to ETF Database data. HTEC tracks the ROBO Global Health Technology and Innovation Index. The strategy, which launched in 2019, targets global healthcare tech firms generating revenue from medical and healthcare services. The team behind the index looks at companies operating in diagnostics, robotics, genomics, medical instruments, and more. That proprietary index has helped the ETF outperform its ETF Database Category average on a YTD, one-year, and three-year basis. HTEC has returned 24.7% YTD, based on that data. Recognizing that approach and the fund’s performance, what are some of the advantages the fund offers? Three reasons stand out to consider HTEC’s case for a place among the best health tech ETFs out there. First off, healthcare tech is a structural necessity, due to a massive aging population. As doctor shortages loom in the next 10 years amid rising healthcare costs, AI and tech advances will need to step up. HTEC’s strategic advisors can help it navigate that landscape and potentially stand out compared to rivals. Secondly, the index eschews the broad pharma buckets in favor of a 1–100 score built on tech and market leadership, innovation-driven revenue, and investment levels. That lets innovation really drive the index, rather than legacy megacaps. See more: AI & Robotics Selloff Creates Disconnect Between Valuations & Fundamentals Finally, HTEC rebalances quarterly, allowing the fund to pick up new IPOs and pivot faster than many other index strategies in the space. Together, that has seen the index surpass $500 million in asset tracking recently for the first time. For those looking for an ETF to take a different, exciting approach to the AI revolution, HTEC can appeal. Looking for regular updates? Subscribe here for weekly insights on robotics, AI, and healthcare technology, delivered straight to your inbox. vettafi.com is owned by VettaFi LLC (“VettaFi”). VettaFi is the index provider for HTEC, for which it receives an index licensing fee. However, HTEC is not issued, sponsored, endorsed, or sold by VettaFi. VettaFi and its affiliates have no obligation or liability in connection with the issuance, administration, marketing, or trading of HTEC.

More Commentary

Get Paid to Wait on an Alphabet Rebound With This ETF
BY | ETF Database
4:34 am ET 11/05/26 | 59 VIEWS
Healthcare Stocks Face Policy Split After Midterm
BY | ETF Database
8:50 am ET 11/05/26 | 9 VIEWS
Wall Street Tightened Its Grip on Bitcoin ETFs in Q2
BY | ETF Database
8:18 am ET 11/05/26 | 10 VIEWS
View more Commentary

Search Commentary

Enter Keyword(s)
Filter Results

Performance data shown is past performance and is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore you have a gain or loss when you sell your shares. For standard quarterly performance, go to the fund's Snapshot page by clicking on the ETF/ETP's symbol.

ETFs may trade at a premium or discount to their NAV and are subject to the market fluctuations of their underlying investments.

For iShares ETFs, Fidelity receives compensation from the ETF sponsor and/or its affiliates in connection with an exclusive long-term marketing program that includes promotion of iShares ETFs and inclusion of iShares funds in certain FBS platforms and investment programs. Please note, this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral. Additional information about the sources, amounts, and terms of compensation can be found in the ETF's prospectus and related documents. Fidelity may add or waive commissions on ETFs without prior notice. BlackRock and iShares are registered trademarks of BlackRock, Inc. and its affiliates.

FBS receives compensation from the fund's advisor or its affiliates in connection with a marketing program that includes the promotion of this security and other ETFs to customers ("Marketing Program"). The Marketing Program creates incentives for FBS to encourage the purchase of certain ETFs. Additional information about the sources, amounts, and terms of compensation is in the ETF's prospectus and related documents. Please note that this security will not be marginable for 30 days from the settlement date, at which time it will automatically become eligible for margin collateral.

News, commentary (including "Related Symbols") and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended to help self-directed investors evaluate exchange traded products (ETPs), including, but limited to exchange traded funds (ETFs) and exchange traded notes (ETNs). Criteria and inputs entered, including the choice to make ETP comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a particular security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating ETPs. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use. Determine which securities are right for you based on your investment objectives, risk tolerance, financial situation and other individual factors and re-evaluate them on a periodic basis.

Before investing in any exchange traded product, you should consider its investment objective, risks, charges and expenses. Contact Fidelity for a prospectus, offering circular or, if available, a summary prospectus containing this information. Read it carefully.